Jefferies Financial Group Initiates Coverage on Neuren Pharmaceuticals (OTCMKTS:NURPF)

Jefferies Financial Group started coverage on shares of Neuren Pharmaceuticals (OTCMKTS:NURPFGet Rating) in a report issued on Wednesday morning, The Fly reports. The firm issued a buy rating on the stock.

Shares of NURPF opened at 2.60 on Wednesday. Neuren Pharmaceuticals has a 52-week low of 1.08 and a 52-week high of 3.30.

Neuren Pharmaceuticals Company Profile (Get Rating)

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome.

Further Reading

The Fly logo

Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.